Preclinical study supports clinical trial of Affimed NK cells, MD Anderson says » 15:5305/1305/13/21
Cytokine-activated natural killer, or NK, cells derived from donated umbilical cord blood, combined with an investigational bispecific antibody targeting CD16a and CD30 known as AFM13, displayed potent anti-tumor activity against CD30+ lymphoma cells, according to a new preclinical study from researchers at The University of Texas MD Anderson Cancer Center. Affimed's AFM13 is a proprietary bispecific antibody designed to bind to CD16a on NK cells and CD30 on lymphoma cells. The findings were published today in Clinical Cancer Research, a journal of the American Association for Cancer Research, the center reported. Senior author Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation and Cellular Therapy, said, "This preclinical work provided proof of principle for NK cells precomplexed with AFM13, suggesting that they can effectively eliminate lymphoma cells expressing CD30 and warrant further clinical testing." Reference Link
|Over a month ago|
Xoma adds three Affimed ICE programs to royalty portfolio » 09:1404/1504/15/21
XOMA Corporation (XOMA)…
XOMA Corporation (XOMA) announced its portfolio of potential future milestone and royalty assets has increased with the addition of three Affimed N.V. (AFMD) innate cell engager programs for which XOMA could receive future economics. In 2006, Affimed licensed certain XOMA technologies to further its research and discovery efforts. AFM13, which has Orphan Drug designation from the U.S. Food and Drug Administration, is a first-in-class CD30/CD16A ICE generated from Affimed's ROCK platform that induces specific and selective killing of CD30-positive tumor cells by engaging and activating natural killer cells and macrophages, thereby leveraging the power of the body's own innate immune system. Affimed currently is studying AFM13 in combination with cord blood-derived allogeneic natural killer cells in cooperation with the MD Anderson Cancer Center in Houston. AFM24 is a tetravalent, bispecific EGFR- and CD16A-binding ICE also generated from Affimed's ROCK platform. AFM24 uses the cytotoxic potential of the innate immune system by redirecting and activating NK cells and macrophages to kill EGFR-positive cancer cells through antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis, respectively. XOMA is eligible to receive undisclosed payments on future commercial sales of each of the three ICE molecules and any pre-loaded NK cells containing the ICE molecules. Additionally, XOMA is eligible to receive an undisclosed milestone for each program on achieving marketing approval.
Ridgeback Capital reports 5.5% passive stake in Affimed » 16:3104/1404/14/21
Ridgeback Capital disclosed a 5.5% stake in Affimed, which represents 6.45M shares. The filing does not allow for activism.
Affimed to hold a conference call » 15:5504/1404/14/21
Management discusses the…
Affimed to hold a conference call » 04:5504/1404/14/21
Management discusses the…
Affimed price target raised to $15 from $12 at BMO Capital » 07:0504/1204/12/21
BMO Capital analyst Do…
BMO Capital analyst Do Kim raised the firm's price target on Affimed to $15 from $12 and keeps an Outperform rating on the shares. The analyst is updating his model with Hodgkin lymphoma indication probability of success increasing to 60% from 35% after the positive update from the MD Anderson Cancer Center study, with early responses confirming AFM13+cbNK cell benefit in highly refractory HL patients. The data validates Affimed's recent collaborations with NK cell companies, NKGen and Artiva, Kim tells investors in a research note.
Affimed highlights potential of Innate Cell Engager AFM24 at AACR » 06:3504/1204/12/21
Affimed announces pre-clinical data on its Innate Cell Engager AFM24 as monotherapy and in combination with adoptively transferred NK cells at the American Association for Cancer Research Virtual Annual Meeting. AFM24, an EGFR/CD16A-binding ICE, mediates antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis and has the potential to overcome toxicity and resistance hurdles associated with current EGFR signaling inhibitors through its differentiated mechanism of action. AFM24 induces NK cell-mediated ADCC against EGFR-expressing tumor cells even in the presence of competing IgG and can induce potent cell killing in tumors independent of KRAS mutations. In addition, data from a xenograft mouse model demonstrate that AFM24 in combination with adoptively transferred NK cells results in dose-dependent tumor regression. "AFM24's novel mechanism of action is independent of EGFR signaling and has the potential to change the treatment paradigm for EGFR-expressing solid tumors," said Dr. Arndt Schottelius, Affimed's Chief Scientific Officer. "Demonstrating that AFM24, in combination with NK cells, shows tumor regression in vivo is an important pre-clinical proof of concept. Combination therapies with NK cells could broaden the potential AFM24 opportunities to treat a range of EGFR-expressing malignancies."
Affimed to hold a conference call » 16:0004/0904/09/21
Management discusses the…
Fly Intel: Wall Street's top stories at midday » 12:5404/0904/09/21
BA, AMZN, CCK, AZN, JNJ, AFMD, LEVI, PRVB, JKS
The major averages are…
Fly Intel: Pre-market Movers » 08:5104/0904/09/21
GLSI, AFMD, CELC, FUBO, SUNW, JKS, TSM, IMOS, GSL, PRVB
Check out this morning's…